Every 8-K that ProAssurance Corporation (PRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRA filings page.
ProAssurance Corporation completed its merger with The Doctors Company, with each outstanding share of ProAssurance common stock converted into the right to receive $25.00 in cash, without interest. ProAssurance survives as the merger subsidiary and is now a wholly owned subsidiary of The Doctors Company.
At the effective time, outstanding restricted stock units, performance shares (at target), and deferred stock accounts tied to ProAssurance shares vested or converted and became rights to the same $25.00 per share cash consideration, subject to applicable tax withholding where noted. ProAssurance also fully repaid and terminated its Second Amended and Restated Credit Agreement and released related liens and guarantees.
In connection with the change in control, all prior directors ceased serving, and a new board and officer group, including Richard Anderson as Chairman and CEO, was installed. ProAssurance has requested NYSE delisting via Form 25 and plans to file Form 15 to terminate registration and suspend ongoing Exchange Act reporting, and it has adopted amended and restated charter and bylaws.
ProAssurance Corporation reports that all regulatory approvals required to complete its merger with The Doctors Company have been received. Insurance regulators in all relevant jurisdictions have approved the deal, and U.S. antitrust review under the Hart-Scott Rodino Act previously received early termination.
ProAssurance stockholders had already approved the merger-related proposals at a special meeting held on June 24, 2025. The company now expects the merger to close on June 26, 2026, with ProAssurance becoming a wholly owned subsidiary of The Doctors Company, subject to satisfaction or waiver of remaining customary closing conditions.
ProAssurance Corporation provided an update on its pending merger with The Doctors Company. The merger agreement calls for Jackson Acquisition Corporation, a subsidiary of The Doctors Company, to merge with ProAssurance, leaving ProAssurance as a wholly owned subsidiary.
Shareholders previously approved the merger-related proposals, and U.S. antitrust review under the Hart-Scott Rodino Act was cleared through early termination of the waiting period. As of June 2, 2026, The Doctors Company has received final insurance regulatory approvals in Alabama, the District of Columbia, Illinois, Missouri, Pennsylvania, Texas, Vermont, Lloyd’s of London, and the Cayman Islands Monetary Authority, while review in California remains pending.
The company notes that the timing of California’s decision is uncertain and outside its control, but, based on progress toward satisfying closing conditions, it continues to anticipate closing the transaction by June 30, 2026. The filing also includes extensive forward-looking statement cautions outlining risks that could cause actual outcomes to differ.
ProAssurance Corporation reported a solid turnaround in first-quarter 2026 results. Net income was $8.5 million, or $0.16 per diluted share, compared with a loss in the prior-year quarter. Non-GAAP operating income rose to $12.7 million, or $0.25 per diluted share, up 86.7% from 2025.
Total revenues were $262.6 million, down 3.5%, as net premiums earned declined but underwriting and loss expenses fell faster, improving the Non-GAAP combined ratio to 109.9% from 112.2%. Consolidated net investment income increased 8.2%, while book value per share slipped to $25.94 due to lower long-term investment values; Non-GAAP adjusted book value per share edged up to $27.86.
The Specialty P&C segment’s Non-GAAP combined ratio improved to 105.9%, helped by $3.0 million of favorable prior-year reserve development. Workers’ compensation posted a higher 114.1% combined ratio. Management reiterated its plan to close the pending merger with The Doctors Company by June 30, 2026, noting most required insurance regulatory approvals have been obtained and others remain under review.
ProAssurance Corporation reported stronger fourth-quarter and mixed full-year 2025 results while advancing its planned merger with The Doctors Company. For the quarter ended December 31, 2025, net income was $33.4 million, or $0.64 per diluted share, and Non-GAAP operating income was $42.4 million, or $0.82 per diluted share, both more than double the prior year’s quarter.
For full-year 2025, net income was $50.9 million, or $0.99 per diluted share, slightly below 2024, but Non-GAAP operating income rose to $83.9 million, or $1.62 per diluted share, from $50.2 million, or $0.98 per diluted share. The consolidated Non-GAAP combined ratio improved to 104.2% for the year and 90.3% in the fourth quarter, helped by $53.1 million of favorable prior-year reserve development in Medical Professional Liability. Book value per share increased to $26.24 from $23.49, and Non-GAAP adjusted book value per share rose to $27.82.
The company highlighted continued premium rate increases in its Specialty P&C segment and stable retention of 84%. Management reiterated that the merger with The Doctors Company is progressing, with multiple state regulatory approvals obtained and remaining reviews in California and Pennsylvania still pending, and continues to be anticipated to close by June 30, 2026, subject to final regulatory approvals.
ProAssurance Corporation reports a compensation decision tied to its pending merger with The Doctors Company. To address potential “excess parachute payment” issues under Section 280G of the tax code, the board’s Compensation Committee, in consultation with TDC and pursuant to the merger agreement, approved paying the company’s named executive officers approximately 80% of the annual cash incentive awards that are presently expected for 2025.
On December 5, 2025, the authorized payments were $998,400 for CEO Edward L. Rand, Jr., $369,873 for CFO Dana S. Hendricks, $381,998 for EVP/General Counsel Jeffrey P. Lisenby, $348,098 for Eastern Alliance Insurance Group President Kevin M. Shook, and $450,000 for Medical Professional Liability President Robert D. Francis. The committee based its decision on its assessment of the likelihood of achieving 2025 performance targets outlined in the 2025 proxy statement.
ProAssurance Corporation filed an 8‑K stating it furnished a news release with results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The company also updated its online disclosure of its entire investment portfolio through September 30, 2025, available under Quarterly Results in the Financial Information section of its Investor Relations website. The furnished information, including Exhibit 99.1, is not deemed “filed” under the Exchange Act.
Date: August 5, 2025. Event: ProAssurance Corporation (PRA) furnished a news release reporting results of operations for the quarter ended June 30, 2025 as Exhibit 99.1 to this Form 8-K.
Disclosure: The company also updated online disclosure of its entire investment portfolio with holdings through June 30, 2025, available under Quarterly Results in the Financial Information section of its Investor Relations website. The filing states the furnished information is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated. The Form 8-K is signed by Jeffrey P. Lisenby, General Counsel.
ProAssurance Corporation (NYSE: PRA) reported that shareholders overwhelmingly approved all proposals connected with its pending merger with The Doctors Company at a special meeting held on 24 June 2025.
• Merger Agreement adoption: 38,225,337 shares voted FOR, just 363,050 AGAINST and 22,192 ABSTAIN; no broker non-votes were recorded. Support exceeded 99% of votes cast, comfortably surpassing any approval threshold.
• Say-on-Pay (merger-related compensation): 31,191,544 FOR, 7,185,578 AGAINST, 233,457 ABSTAIN—an 81% approval rate on an advisory basis.
• Adjournment proposal: Not required because quorum (≈75.6% of outstanding 51,070,243 shares) was achieved and the merger proposal passed.
Under the Agreement and Plan of Merger signed 19 March 2025, Jackson Acquisition Corporation (a wholly owned subsidiary of The Doctors Company) will merge with and into ProAssurance, making ProAssurance a wholly owned subsidiary of The Doctors Company. Management currently expects closing in the first half of 2026, subject to regulatory clearances and other customary conditions.
The filing reiterates extensive forward-looking risk factors, including regulatory approvals, potential litigation, business disruption, personnel retention and market reactions during the pre-closing period. A related news release (Exhibit 99.1) announcing the vote results was issued the same day.